Immutep (IMMP) Competitors

Immutep (NASDAQ:IMMP) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, community ranking, media sentiment, analyst recommendations, institutional ownership and risk.

Does the MarketBeat Community believe in IMMP or COLL?

Collegium Pharmaceutical received 79 more outperform votes than Immutep when rated by MarketBeat users. However, 72.56% of users gave Immutep an outperform vote while only 65.49% of users gave Collegium Pharmaceutical an outperform vote.

Company	Underperform	Outperform
Immutep	Outperform Votes 312 72.56%	Underperform Votes 118 27.44%
Collegium Pharmaceutical	Outperform Votes 391 65.49%	Underperform Votes 206 34.51%

Does the media prefer IMMP or COLL?

In the previous week, Collegium Pharmaceutical had 1 more articles in the media than Immutep. MarketBeat recorded 6 mentions for Collegium Pharmaceutical and 5 mentions for Immutep. Collegium Pharmaceutical's average media sentiment score of 1.05 beat Immutep's score of 0.77 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immutep	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Collegium Pharmaceutical	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, IMMP or COLL?

Immutep has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500.

Do analysts recommend IMMP or COLL?

Immutep presently has a consensus price target of $8.50, indicating a potential upside of 408.98%. Collegium Pharmaceutical has a consensus price target of $43.60, indicating a potential upside of 61.12%. Given Immutep's stronger consensus rating and higher possible upside, research analysts plainly believe Immutep is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immutep	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Collegium Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Is IMMP or COLL more profitable?

Collegium Pharmaceutical has a net margin of 14.78% compared to Immutep's net margin of 0.00%. Collegium Pharmaceutical's return on equity of 104.67% beat Immutep's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immutep	N/A	N/A	N/A
Collegium Pharmaceutical	14.78%	104.67%	18.38%

Which has better valuation & earnings, IMMP or COLL?

Collegium Pharmaceutical has higher revenue and earnings than Immutep.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immutep	$5.14M	47.45	-$28.01M	N/A	N/A
Collegium Pharmaceutical	$631.45M	1.38	$48.15M	$1.86	14.55

Do insiders and institutionals have more ownership in IMMP or COLL?

2.3% of Immutep shares are held by institutional investors. 3.1% of Immutep shares are held by insiders. Comparatively, 2.5% of Collegium Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Collegium Pharmaceutical beats Immutep on 9 of the 16 factors compared between the two stocks.